GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
N

NewAmsterdam Pharma Company NAMS · USD

Health Care · US listing · 🇺🇸 United States

Compare

18.41

-5.64%

Close of 20 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

Price performance

Chart by TradingView, with its own licensed prices

NewAmsterdam Pharma Company — daily NAMS Delayed
Market value
$2.12bn
Last close × shares
Volume
1.7m
Shares, 20 Nov 2026

About NewAmsterdam Pharma Company

From its filings with the US Securities and Exchange Commission

SEC filings

NewAmsterdam Pharma Company is based in Narrden, Netherlands and is incorporated in Netherlands. Its shares trade on Nasdaq under the ticker NAMS. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $22.5m and a net loss of $203.8m. At that date it held total assets of $769.3m and shareholders' equity of $683.4m.

In its own words

Obicetrapib is a next-generation, oral, low-dose, highly selective CETP inhibitor that we are developing to potentially overcome the limitations of current LDL-C lowering treatments. We believe that obicetrapib has the potential to be a once-daily oral CETP inhibitor for lowering LDL-C, if approved. In each of our Phase 3 clinical trials, BROADWAY and BROOKLYN, evaluating obicetrapib as an adjunct to high-intensity statin therapy, obicetrapib met its primary and secondary endpoints, with statistically significant reductions in LDL-C observed. In our Phase 3 TANDEM clinical trial, evaluating obicetrapib in combination with ezetimibe as an adjunct to high-intensity statin therapy, obicetrapib in combination with ezetimibe met its primary and secondary endpoints, with statistically significant reductions in LDL-C observed. In five of our Phase 2 clinical trials, TULIP, ROSE, OCEAN, ROSE2 and our Japan Phase 2b clinical trial, evaluating obicetrapib as a monotherapy or a combination therapy with ezetimibe 10 mg, we observed statistically significant LDL-C lowering. In each of these trials, side effects were similar in frequency and severity to placebo including muscle-related side effects and drug-related treatment-emergent serious adverse events (“TESAEs”). We have observed obicetrapib to be well tolerated in an aggregate of over 3,500 patients with low or moderately elevated LDL-C levels (“dyslipidemia”) in our clinical trials to date.

Quoted from its 10-K, filed 18 Feb 2026. Read the filing on SEC.gov ↗

More about NewAmsterdam Pharma Company →

Latest on NewAmsterdam Pharma Company

Our reporting

Next results

17 Feb 2027

Due on 17 Feb 2027. Analysts expect earnings of -0.44 a share.

Other Health Care listings

Scenario calculator

Try your own numbers. This is arithmetic, not a forecast.

Interactive

Gain or loss

—

Return

—

Leaves out fees, taxes and financing.

Frequently asked questions

What is NewAmsterdam Pharma Company's ticker?

NewAmsterdam Pharma Company trades as NAMS on its US listing, under ISIN NL00150012L7.

What was NewAmsterdam Pharma Company's last closing price?

18.41 on 20 Nov 2026. The figure is in USD and is never converted.

When does NewAmsterdam Pharma Company next report results?

Results are expected on 17 Feb 2027, according to our data supplier.

Sources and methodology

Chart
TradingView
Close and company data
SEC filings and our data supplier
News
Our reporting

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.